Advanced Filter

Filter by Group

Filter by Market Availability

Displaying drugs 10876 - 10900 of 11783 in total
Dimenoxadol is an opioid analgesic which produces typical opioid effects such as analgesia and sedation. It is structurally similar to methadone and is a benzilic acid derivative. In the United States it is classified as a Schedule I controlled drug.
Experimental
Illicit
Matched Description: … In the United States it is classified as a Schedule I controlled drug. ... It is structurally similar to methadone and is a benzilic acid derivative. …
4-(4-fluoro-phenylazo)-5-imino-5H-pyrazol-3-ylamine is a solid. This compound belongs to the fluorobenzenes. These are compounds containing one or more fluorine atoms attached to a benzene ring. This substance targets the protein methionine aminopeptidase.
Experimental
Matched Description: … 4-(4-fluoro-phenylazo)-5-imino-5H-pyrazol-3-ylamine is a solid. ... These are compounds containing one or more fluorine atoms attached to a benzene ring. …
Trefentanil (A-3665) is a fentanyl analogue opioid developed in 1992. It is more potent and shorter acting than alfentanil. Trefentanil is not used in clinics due to the severity of its respiratory depression, though it is still used in research.
Experimental
Matched Description: … Trefentanil (A-3665) is a fentanyl analogue opioid developed in 1992. …
Bempegaldesleukin is under investigation in clinical trial NCT03729245 (A Study of NKTR-214 in Combination With Nivolumab Compared With the Investigator's Choice of a Tyrosine Kinase Inhibitor (TKI) Therapy (Either Sunitinib or Cabozantinib Monotherapy) for Advanced Metastatic Renal Cell Carcinoma (RCC)).
Investigational
Matched Description: … Bempegaldesleukin is under investigation in clinical trial NCT03729245 (A Study of NKTR-214 in Combination ... With Nivolumab Compared With the Investigator's Choice of a Tyrosine Kinase Inhibitor (TKI) Therapy …
LX6171 is an oral drug candidate that was generated by Lexicon medicinal chemists and is being developed to treat disorders characterized by cognitive impairment, such as Alzheimer's disease, schizophrenia or vascular dementia.
Investigational
Volixibat, also known as SHP626 or LUM002, is an investigational drug that will potentially be used for the treatment of Non-Alcoholic Steatohepatitis (NASH). If approved for use, it will be the first available agent for the treatment of NASH. Volixibat is a selective inhibitor of the apical sodium-dependent bile acid...
Experimental
Investigational
Matched Description: … Volixibat is a selective inhibitor of the apical sodium-dependent bile acid transporter (ASBT), a transmembrane ... Inhibiting this enzyme results in a decrease of bile acids returning to the liver, which is helpful for ... granted fast track status by the Food and Drug Administration due to promising initial results and a
Tasosartan is a long-acting angiotensin II (AngII) receptor blocker. Its long duration of action has been attributed to its active metabolite enoltasosartan. It is used to treat patients with essential hypertension.
Experimental
Matched Description: … Tasosartan is a long-acting angiotensin II (AngII) receptor blocker. …
DP-b99 is a newly developed lipophilic, cell permeable derivative of BAPTA (1,2-bis(2-aminophenoxy)ethane-N,N,N',N'-tetraacetic acid), that is under development as a neuroprotectant for the potential treatment of stroke, head trauma and neurological damage associated with coronary artery bypass graft.
Investigational
Matched Description: … DP-b99 is a newly developed lipophilic, cell permeable derivative of BAPTA (1,2-bis(2-aminophenoxy)ethane-N ... ,N,N',N'-tetraacetic acid), that is under development as a neuroprotectant for the potential treatment …
An analog of inosine with a methylthio group replacing the hydroxyl group in the 6-position.
Experimental
Matched Description: … An analog of inosine with a methylthio group replacing the hydroxyl group in the 6-position. …
IPH-2101 (NN-1975), a fully human monoclonal antibody developed for patients with acute myeloid leukemia.
Investigational
Matched Description: … IPH-2101 (NN-1975), a fully human monoclonal antibody developed for patients with acute myeloid leukemia …
MK-0482 is a novel humanized IgG4 monoclonal antibody targeting the immunoglobulin-like transcript (ILT) 3.
Investigational
Matched Description: … MK-0482 is a novel humanized IgG4 monoclonal antibody targeting the immunoglobulin-like transcript (ILT …
KF-0210 is a small molecule developed by Keythera Pharmaceuticals. It is being investigated for cancers.
Investigational
Matched Description: … KF-0210 is a small molecule developed by Keythera Pharmaceuticals. …
PLG-0206 is a peptide antibiotic under investigation for the treatment of periprosthetic joint infections.
Investigational
Matched Description: … PLG-0206 is a peptide antibiotic under investigation for the treatment of periprosthetic joint infections …
Ilomastat is a broad-spectrum matrix metalloproteinase inhibitor.
Experimental
Matched Description: … Ilomastat is a broad-spectrum matrix metalloproteinase inhibitor. …
Glibornuride is a sulfonylurea-type anti-diabetic drug.
Investigational
Withdrawn
Matched Description: … Glibornuride is a sulfonylurea-type anti-diabetic drug. …
Bamifylline is a selective A1 adenosine receptor antagonist.
Experimental
Matched Description: … Bamifylline is a selective A1 adenosine receptor antagonist. …
Protego-PD is a post-delivery placental extract.
Investigational
Matched Description: … Protego-PD is a post-delivery placental extract. …
Elocalcitol is a calcitriol analog for inhibition of prostate cell growth; in phase II clinical trial in patients with benign prostate hyperplasia (4/2004).
Investigational
Matched Description: … Elocalcitol is a calcitriol analog for inhibition of prostate cell growth; in phase II clinical trial …
SUVN-G3031 is under investigation in clinical trial NCT02342041 (A Study to Investigate the Safety, Tolerability and Pharmacokinetics of SUVN-G3031 in Healthy Subjects).
Investigational
Matched Description: … SUVN-G3031 is under investigation in clinical trial NCT02342041 (A Study to Investigate the Safety, Tolerability …
Pimodivir is under investigation in clinical trial NCT02658825 (A Study to Evaluate the Effect of JNJ-63623872 on Cardiac Repolarization Interval in Healthy Participants).
Investigational
Matched Description: … Pimodivir is under investigation in clinical trial NCT02658825 (A Study to Evaluate the Effect of JNJ …
Palladium Pd-103 is under investigation in clinical trial NCT00247312 (Pd-103 Dose De-Escalation for Early Stage Prostate Cancer: A Prospective Randomized Trial).
Investigational
Matched Description: … investigation in clinical trial NCT00247312 (Pd-103 Dose De-Escalation for Early Stage Prostate Cancer: A
Domagrozumab is under investigation in clinical trial NCT01616277 (A Phase 1 Study To Evaluate The Safety And Tolerability Of PF-06252616 In Healthy Subjects).
Investigational
Matched Description: … Domagrozumab is under investigation in clinical trial NCT01616277 (A Phase 1 Study To Evaluate The Safety …
CB-1158 is under investigation in clinical trial NCT03910530 (A Study of INCMGA00012, INCB001158, and the Combination in Japanese Participants With Advanced Solid Tumors).
Investigational
Matched Description: … CB-1158 is under investigation in clinical trial NCT03910530 (A Study of INCMGA00012, INCB001158, and …
Rovatirelin is under investigation in clinical trial NCT01384435 (A Phase II Double Blind Comparative Study of KPS-0373 in Patients With Spinocerebellar Degeneration (SCD)).
Investigational
Matched Description: … Rovatirelin is under investigation in clinical trial NCT01384435 (A Phase II Double Blind Comparative …
GSK2798745 is under investigation in clinical trial NCT03372603 (A Study to Assess the Effectiveness and Side Effects of GSK2798745 in Participants With Chronic Cough).
Investigational
Matched Description: … GSK2798745 is under investigation in clinical trial NCT03372603 (A Study to Assess the Effectiveness …
Displaying drugs 10876 - 10900 of 11783 in total